



Resolution

of the Federal Joint Committee on the discontinuation of the benefit assessment of Belimumab in the procedure according to Section 35a SGB V

of 1 July 2021

The Federal Joint Committee (G-BA) decided the following at its session on 1 July 2021:

- I. The procedure for the benefit assessment of belimumab according to Section 35a of the German Social Code, Book V (SGB V) in the therapeutic indication in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis is discontinued.

- II. The resolution will enter into force on the day of its publication on the internet on the G-BA website on 1 July 2021.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 1 July 2021

Federal Joint Committee
in accordance with Section 91 SGB V
The Chair

Prof. Hecken